<b>Background:</b> Chimeric antigen receptor T cells treatment targeting B cell maturation antigen (BCMA) is an emerging treatment option for relapsed/refractory multiple myeloma (RRMM) and has demonstrated outstanding outcomes in clinical studies. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.